• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

新型氟喹诺酮酮内酯司帕沙星（CEM-101）对大量临床淋病奈瑟菌分离株和国际参考菌株的体外活性，包括那些具有高水平抗菌耐药性的菌株：淋病的潜在治疗选择？

In vitro activity of the new fluoroketolide solithromycin (CEM-101) against a large collection of clinical Neisseria gonorrhoeae isolates and international reference strains, including those with high-level antimicrobial resistance: potential treatment option for gonorrhea?

机构信息

WHO Collaborating Centre for Gonorrhoea and other STIs, National Reference Laboratory for Pathogenic Neisseria, Department of Laboratory Medicine, Microbiology, Örebro University Hospital, Örebro, Sweden.

出版信息

Antimicrob Agents Chemother. 2012 May;56(5):2739-42. doi: 10.1128/AAC.00036-12. Epub 2012 Feb 21.

DOI:10.1128/AAC.00036-12
PMID:22354296
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC3346660/
Abstract

Gonorrhea may become untreatable, and new treatment options are essential. We investigated the in vitro activity of the first fluoroketolide, solithromycin. Clinical Neisseria gonorrhoeae isolates and reference strains (n = 246), including the two extensively drug-resistant strains H041 and F89 and additional isolates with clinical cephalosporin resistance and multidrug resistance, were examined. The activity of solithromycin was mainly superior to that of other antimicrobials (n = 10) currently or previously recommended for gonorrhea treatment. Solithromycin might be an effective treatment option for gonorrhea.

摘要

淋病可能变得无法治疗，因此需要新的治疗方案。我们研究了首个氟喹诺酮酮内酯类药物——索利霉素的体外活性。检测了临床淋病奈瑟菌分离株和参考株（n = 246），包括两种广泛耐药菌株 H041 和 F89 以及其他具有临床头孢菌素耐药性和多药耐药性的分离株。索利霉素的活性主要优于目前或以前推荐用于淋病治疗的其他十种（n = 10）抗菌药物。索利霉素可能是淋病的一种有效治疗选择。

相似文献

1
In vitro activity of the new fluoroketolide solithromycin (CEM-101) against a large collection of clinical Neisseria gonorrhoeae isolates and international reference strains, including those with high-level antimicrobial resistance: potential treatment option for gonorrhea?新型氟喹诺酮酮内酯司帕沙星（CEM-101）对大量临床淋病奈瑟菌分离株和国际参考菌株的体外活性，包括那些具有高水平抗菌耐药性的菌株：淋病的潜在治疗选择？
Antimicrob Agents Chemother. 2012 May;56(5):2739-42. doi: 10.1128/AAC.00036-12. Epub 2012 Feb 21.
2
In vitro activity of the new fluoroketolide solithromycin (CEM-101) against macrolide-resistant and -susceptible Mycoplasma genitalium strains.新型氟代酮内酯类药物索利霉素（CEM-101）对大环内酯类耐药及敏感生殖支原体菌株的体外活性
Antimicrob Agents Chemother. 2014 Jun;58(6):3151-6. doi: 10.1128/AAC.02411-14. Epub 2014 Mar 17.
3
In vitro activities of the novel bicyclolides modithromycin (EDP-420, EP-013420, S-013420) and EDP-322 against MDR clinical Neisseria gonorrhoeae isolates and international reference strains.新型双环内酯类药物莫昔克丁（EDP-420、EP-013420、S-013420）和 EDP-322 对耐多药临床淋病奈瑟菌分离株和国际参考菌株的体外活性。
J Antimicrob Chemother. 2015 Jan;70(1):173-7. doi: 10.1093/jac/dku344. Epub 2014 Sep 1.
4
In vitro activity of ertapenem versus ceftriaxone against Neisseria gonorrhoeae isolates with highly diverse ceftriaxone MIC values and effects of ceftriaxone resistance determinants: ertapenem for treatment of gonorrhea?厄他培南与头孢曲松对头孢曲松 MIC 值高度多样化的淋病奈瑟菌分离株的体外活性及头孢曲松耐药决定因素的影响：厄他培南治疗淋病？
Antimicrob Agents Chemother. 2012 Jul;56(7):3603-9. doi: 10.1128/AAC.00326-12. Epub 2012 Apr 30.
5
Solithromycin (CEM-101): A New Fluoroketolide Antibiotic and Its Role in the Treatment of Gonorrhea.索利霉素（CEM-101）：一种新型氟代酮内酯类抗生素及其在淋病治疗中的作用。
J Pharm Pract. 2018 Apr;31(2):195-201. doi: 10.1177/0897190017708073. Epub 2017 May 11.
6
Determination of Disk Diffusion and MIC Quality Control Guidelines for Solithromycin, a Novel Fluoroketolide Antibacterial, against Neisseria gonorrhoeae.新型氟代酮内酯类抗菌药物索利霉素对淋病奈瑟菌的纸片扩散法及最低抑菌浓度质量控制指南的测定
J Clin Microbiol. 2015 Dec;53(12):3888-90. doi: 10.1128/JCM.02250-15. Epub 2015 Sep 16.
7
Gentamicin Susceptibility among a Sample of Multidrug-Resistant Neisseria gonorrhoeae Isolates in India.印度多重耐药淋病奈瑟菌分离株样本中的庆大霉素敏感性
Antimicrob Agents Chemother. 2016 Nov 21;60(12):7518-7521. doi: 10.1128/AAC.01907-16. Print 2016 Dec.
8
High-level cefixime- and ceftriaxone-resistant Neisseria gonorrhoeae in France: novel penA mosaic allele in a successful international clone causes treatment failure.法国高水平头孢克肟和头孢曲松耐药淋病奈瑟菌：一种成功的国际克隆中的新型 penA 嵌合等位基因导致治疗失败。
Antimicrob Agents Chemother. 2012 Mar;56(3):1273-80. doi: 10.1128/AAC.05760-11. Epub 2011 Dec 12.
9
Emergence of multidrug-resistant, extensively drug-resistant and untreatable gonorrhea.出现了耐多药、广泛耐药和无法治疗的淋病。
Future Microbiol. 2012 Dec;7(12):1401-22. doi: 10.2217/fmb.12.117.
10
Emergence and evolution of internationally disseminated cephalosporin-resistant Neisseria gonorrhoeae clones from 1995 to 2005 in Japan.1995年至2005年期间日本国际传播的耐头孢菌素淋病奈瑟菌克隆的出现与演变
BMC Infect Dis. 2015 Sep 17;15:378. doi: 10.1186/s12879-015-1110-x.

引用本文的文献

1
Emerging threat of antimicrobial resistance in Neisseria gonorrhoeae: pathogenesis, treatment challenges, and potential for vaccine development.淋病奈瑟菌中抗菌药物耐药性的新出现威胁：发病机制、治疗挑战和疫苗开发的潜力。
Arch Microbiol. 2023 Sep 9;205(10):330. doi: 10.1007/s00203-023-03663-0.
2
Epidemiology, Treatments, and Vaccine Development for Antimicrobial-Resistant Neisseria gonorrhoeae: Current Strategies and Future Directions.耐抗生素淋病奈瑟菌的流行病学、治疗方法和疫苗研发：当前策略和未来方向。
Drugs. 2021 Jul;81(10):1153-1169. doi: 10.1007/s40265-021-01530-0. Epub 2021 Jun 7.
3
and Activities of TP0480066, a Novel Topoisomerase Inhibitor, against Neisseria gonorrhoeae.新型拓扑异构酶抑制剂 TP0480066 对淋病奈瑟菌的作用。
Antimicrob Agents Chemother. 2021 Mar 18;65(4). doi: 10.1128/AAC.02145-20.
4
Neisseria gonorrhoeae Antimicrobial Resistance: Past to Present to Future.淋病奈瑟菌的抗菌药物耐药性：从过去到现在再到未来
Curr Microbiol. 2021 Mar;78(3):867-878. doi: 10.1007/s00284-021-02353-8. Epub 2021 Feb 2.
5
Antimicrobial Resistance in Neisseria gonorrhoeae: Proceedings of the STAR Sexually Transmitted Infection-Clinical Trial Group Programmatic Meeting.淋病奈瑟菌的耐药性：STAR 性传播感染临床研究组计划会议记录。
Sex Transm Dis. 2019 Mar;46(3):e18-e25. doi: 10.1097/OLQ.0000000000000929.
6
Selective Inhibition of by a Dithiazoline in Mixed Infections with .二硫杂环戊烯对 的选择性抑制及其在 混合感染中的作用。
Antimicrob Agents Chemother. 2018 Nov 26;62(12). doi: 10.1128/AAC.00826-18. Print 2018 Dec.
7
Future Prospects for Treatment.治疗的未来前景
Antibiotics (Basel). 2018 Jun 15;7(2):49. doi: 10.3390/antibiotics7020049.
8
Identification and Characterization of the Neisseria gonorrhoeae MscS-Like Mechanosensitive Channel.鉴定和表征淋病奈瑟菌 MscS 样机械敏感通道。
Infect Immun. 2018 May 22;86(6). doi: 10.1128/IAI.00090-18. Print 2018 Jun.
9
Multidrug-resistant gonorrhea: A research and development roadmap to discover new medicines.多重耐药性淋病：发现新药的研发路线图。
PLoS Med. 2017 Jul 26;14(7):e1002366. doi: 10.1371/journal.pmed.1002366. eCollection 2017 Jul.
10
Gonorrhea - an evolving disease of the new millennium.淋病——新千年不断演变的疾病。
Microb Cell. 2016 Sep 5;3(9):371-389. doi: 10.15698/mic2016.09.524.

本文引用的文献

1
Antibiotic resistance in Neisseria gonorrhoeae: origin, evolution, and lessons learned for the future.淋病奈瑟菌的抗生素耐药性：起源、进化以及对未来的启示。
Ann N Y Acad Sci. 2011 Aug;1230:E19-28. doi: 10.1111/j.1749-6632.2011.06215.x.
2
Neisseria gonorrhoeae with high-level resistance to azithromycin: case report of the first isolate identified in the United States.耐阿奇霉素淋病奈瑟菌高水平耐药：美国首例分离株报告。
Clin Infect Dis. 2012 Mar;54(6):841-3. doi: 10.1093/cid/cir929. Epub 2011 Dec 19.
3
High-level cefixime- and ceftriaxone-resistant Neisseria gonorrhoeae in France: novel penA mosaic allele in a successful international clone causes treatment failure.法国高水平头孢克肟和头孢曲松耐药淋病奈瑟菌：一种成功的国际克隆中的新型 penA 嵌合等位基因导致治疗失败。
Antimicrob Agents Chemother. 2012 Mar;56(3):1273-80. doi: 10.1128/AAC.05760-11. Epub 2011 Dec 12.
4
First Neisseria gonorrhoeae strain with resistance to cefixime causing gonorrhoea treatment failure in Austria, 2011.2011 年，奥地利首例对头孢克肟具有耐药性的淋病奈瑟菌菌株导致淋病治疗失败。
Euro Surveill. 2011 Oct 27;16(43):19998.
5
The European gonococcal antimicrobial surveillance programme, 2009.欧洲淋球菌抗菌药物监测项目，2009 年。
Euro Surveill. 2011 Oct 20;16(42):19995.
6
UK national guideline for the management of gonorrhoea in adults, 2011.《2011年英国成人淋病管理国家指南》
Int J STD AIDS. 2011 Oct;22(10):541-7. doi: 10.1258/ijsa.2011.011267.
7
Trends in antimicrobial resistance in Neisseria gonorrhoeae isolated in Canada: 2000-2009.加拿大分离的淋病奈瑟菌中抗菌药物耐药性的趋势：2000-2009 年。
Sex Transm Dis. 2011 Oct;38(10):892-8. doi: 10.1097/OLQ.0b013e31822c664f.
8
Antibiotic-resistant phenotypes and genotypes of Neisseria gonorrhoeae isolates in Japan: identification of strain clusters with multidrug-resistant phenotypes.日本淋病奈瑟菌分离株的抗生素耐药表型和基因型：耐药表型多药耐药菌株群的鉴定。
Sex Transm Dis. 2011 Sep;38(9):871-5. doi: 10.1097/OLQ.0b013e31821d0f98.
9
Cephalosporin susceptibility among Neisseria gonorrhoeae isolates--United States, 2000-2010.淋病奈瑟菌分离株的头孢菌素药敏性——美国，2000-2010 年。
MMWR Morb Mortal Wkly Rep. 2011 Jul 8;60(26):873-7.
10
Is Neisseria gonorrhoeae initiating a future era of untreatable gonorrhea?: detailed characterization of the first strain with high-level resistance to ceftriaxone.淋病奈瑟菌是否开启了无法治愈的淋病的未来时代？：对首例高水平头孢曲松耐药菌株的详细特征描述。
Antimicrob Agents Chemother. 2011 Jul;55(7):3538-45. doi: 10.1128/AAC.00325-11. Epub 2011 May 16.